rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-4-69-75rpcardio-1141Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯPLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPYК ВОПРОСУ О МЕСТЕ БЛОКАТОРОВ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИБойцовС. А.BoytsovS. A.prof-boytsov@mail.ruКолосИ. П.KolosI. P.prof-boytsov@mail.ruРоссийский кардиологический научно-производственный комплекс Росмедтехнологий, 121552 Москва, ул. 3-я Черепковская, 15аРоссияRussian Cardiology Research and Production Center of Rosmedtechnology, Tretya Cherepkovskaya ul. 15a, Moscow, 121552 RussiaRussian Federation200831012016446975Copyright © Boytsov S.A., Kolos I.P., 20162016Бойцов С.А., Колос И.П.Boytsov S.A., Kolos I.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1141

Angiotensin II receptor antagonists (ARA) established their position recently duet to new indications above arterial hypertension (HT). These are chronic heart failure, history of myocardial infarction, atrial fibrillation and metabolic syndrome. Analysis of evidence basis, including recently published biggest international clinical studies, was performed in the article. Data demonstrate that ARA can be effectively and safely used in wide clinical practice for improvement of life quality and life prolongation in patients with HT.

В последние годы блокаторы рецепторов ангиотензина II (БРА) существенно упрочили свои позиции в плане расширения показаний дополнительно к лечению артериальной гипертензии (АГ). Появились такие новые показания, как хроническая сердечная недостаточность, перенесенный инфаркт миокарда, фибрилляция предсердий и метаболический синдром. В статье проведен анализ имеющейся доказательной базы, в том числе с учетом опубликованных недавно результатов крупнейших международных исследований, свидетельствующий о том, что БРА могут безопасно и эффективно применяться в широкой клинической практике для увеличния продолжительности и качества жизни у пациентов с АГ.

блокаторы рецепторов ангиотензинаингибиторы АПФартериальная гипертензияинфаркт миокардамерцательная аритмияangiotensin II receptor antagonistsACE inhibitorsarterial hypertensionmyocardial infarctionatrial fibrillationReferencesMancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.Mochizuki S., Dahlöf B., Shimizu M., et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9.Mochizuki S., Dahlöf B., Shimizu M., et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9.The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.Yusuf S., Diener H.C., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37.Yusuf S., Diener H.C., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37.Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329: 1248-9.Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329: 1248-9.Papademetriou V., Farsang C., Elmfeldt D., et al. Stroke prevention with the angiotensin II type 1- receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175-80.Papademetriou V., Farsang C., Elmfeldt D., et al. Stroke prevention with the angiotensin II type 1- receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175-80.Brenner B.M., Cooper M.E., de Zeeuw D., et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.Brenner B.M., Cooper M.E., de Zeeuw D., et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.Turnbull F., Neal B., Algert C., et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-9.Turnbull F., Neal B., Algert C., et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-9.Reboldi G., Angeli F., Cavallini C., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptors blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008,26:1282-9.Reboldi G., Angeli F., Cavallini C., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptors blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008,26:1282-9.Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.Schrader J., Lüders S., Kulschewski A., et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26.Schrader J., Lüders S., Kulschewski A., et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31.McMurray J. Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate [letter]. BMJ 2005;330;1269.McMurray J. Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate [letter]. BMJ 2005;330;1269.McDonald M.A., Simpson S.H., Ezekowitz J.A. et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005;331;873-9.McDonald M.A., Simpson S.H., Ezekowitz J.A. et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005;331;873-9.Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832–9.Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832–9.Ducharme A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152(1):86-92.Ducharme A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152(1):86-92.Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548-57.Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548-57.Madrid A.H., Bueno M.G., Rebollo J.M. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-6.Madrid A.H., Bueno M.G., Rebollo J.M. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-6.

The authors declare that there are no conflicts of interest present.